Synopsis:
Shukra Pharmaceuticals hit the upper circuit after partnering with Wockhardt Limited for a PAN India distribution tie-up, allowing it to manage and distribute Wockhardt’s key products across government and defence hospitals, strengthening its healthcare presence.
The shares of this leading manufacturer and marketer of pharmaceutical products are in focus after signing a key distribution agreement. In this article, we will dive more into the details.
With a market capitalization of Rs 1,193 crore, the shares of Shukra Pharmaceuticals Ltd made a day high of Rs 27.24 per share, up by 2 percent (upper circuit), from its previous day closing price of Rs 26.71 per share. Over the past five years, the stock has delivered a multibagger return of 11,250 percent.
About the announcement
Shukra Pharmaceuticals Limited has entered into a strategic distribution agreement with Wockhardt Limited, a leading global pharmaceutical company. Under this PAN India authorization, Shukra Pharmaceuticals will represent, distribute, and manage Wockhardt’s products across ESIC/ESIS ( Employees’ State Insurance Corporation / Employees’ State Insurance Scheme) hospitals, defence hospitals, AFMSD (Armed Forces Medical Stores Depot), and DGAFMS (Directorate General Armed Forces Medical Services) units across India.
The non-exclusive authorization, received on September 9, 2025, and valid till March 2026, allows Shukra Pharmaceuticals to quote products, collect orders, raise invoices, and receive payments directly on behalf of Wockhardt Limited.
The partnership covers high-quality, advanced anti-infective formulations, including EMROK (Levonadifloxacin) and MIQNAF® (Nafithromycin), which are breakthrough antibiotics designed to combat critical infections.
This collaboration marks a significant milestone for Shukra Pharmaceuticals, enhancing its presence in institutional and government healthcare networks across India. It is expected to boost revenue visibility, expand operational reach, and create long-term value for shareholders by leveraging India’s growing healthcare and hospital infrastructure. The company’s management believes this development will have a positive and lasting impact on its financial and operational performance.
Also Read: Smallcap stock hits 20% upper circuit after NEO Asset Management plans to invest in the company
Financial Highlights
The company reported a revenue of Rs 5.39 crore in Q1 FY26, up by 69 percent from its Q1 FY25 revenue of Rs 3.18 crore. However, revenue declined by 59 percent from Rs 13.27 crore in its previous quarter.
Regarding its profitability, the company reported a net profit of Rs 1.03 crore in Q1 FY26, up by 110 percent from its Q1 FY25 net profit of Rs 49 lakh. However, it declined by 81 percent from Rs 5.39 crore in its previous quarter.
The stock delivered an ROE and ROCE of 15.90 percent and 21.80 percent respectively, and is currently trading at a high P/E of 118x as compared to its industry average of 33.56x.
Shukra Pharmaceuticals Limited is all about developing, manufacturing, marketing, and exporting a diverse array of pharmaceutical products, both in India and around the globe. Their impressive lineup features everything from antibiotics and anti-bacterial agents to anti-fungal, anti-viral, and anti-malarial medications.
They also offer sedatives, anti-depressants, anti-ulcer drugs, beta blockers, vitamins, corticosteroids, and a variety of other specialty medicines, addressing a wide range of therapeutic needs.
Written by Satyajeet Mukherjee
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
